Background. The RTS,S/AS01 E malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI).
Scientific Review Committee/Institutional Ethics Committee and the Ghana Health Service National Ethical Review Committee in Ghana, the London School of Hygiene and Tropical Medicine Ethics Committee in the United Kingdom, the Swiss Tropical Institute Committee in Switzerland, and the Western Institutional Review Board in the United States.
The independent data monitoring committee appointed to oversee the RTS,S pediatric development program reviewed the ethical, quality, and safety aspects of the study conduct. The study was conducted in accordance with the Helsinki Declaration of 1964 (revised in 1996) and according to Good Clinical Practice guidelines.
GlaxoSmithKline Biologicals was the study sponsor. The Program for Appropriate Technology in Health Malaria Vaccine Initiative cofunded this trial and was involved in all aspects of the study design.
Study research centers. The study was conducted at 3 clinical research centers: Kintampo Health Research Center, Kintampo, Ghana; Ifakara Health Research and Development Centre, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania; and the Albert Schweitzer Hospital, Medical Research Unit Lambaréné, Lambaréné, Gabon. The intensity of malaria transmission in all 3 study sites is intense and perennial [11, [14] [15] [16] [17] .
Study participants. For the recruitment of study participants, lists of potentially eligible infants were generated following community-based information programs in the Bagamoyo and Lambaréné study areas. In Kintampo, the monitoring of births as part of the research center's demographic surveillance system was used. Healthy male and female infants aged 6-10 weeks at the time of the first vaccine dose who had received 1 previous dose of OPV and bacille Calmette-Guérin (BCG) were eligible for enrollment. Written informed consent was obtained from each child's parent or guardian before study procedures were initiated. For nonliterate parents, consent was documented using a thumbprint and a signature by a literate witness.
Randomization and vaccination. Eligible subjects were randomized (1:1:1) to 1 of 3 groups ( Table 1 ). The RTS,S/ AS01 E (0, 1, 2) group received RTS,S/AS01 E at 0, 1, and 2 months-3 doses in coadministration with DTPwHepB/ Hib+OPV. The RTS,S/AS01 E (0, 1, 7) group received RTS,S/ AS01 E at 0, 1, and 7 months-doses 1 and 2 in coadministration with DTPwHepB/Hib+OPV and dose 3 in coadministration with measles and yellow fever vaccines. The control group received EPI vaccines only. Yellow fever vaccine was not administered to infants from Tanzania because it is not included in the EPI vaccination schedule in Tanzania.
Study vaccines. RTS,S/AS01 E , DTPwHepB/Hib (Tritanrix HepB and Hiberix; GlaxoSmithKline Biologicals), measles vaccine (Rouvax; Aventis Pasteur; some subjects from Gabon received the local EPI measles vaccine from the Serum Institute of India Limited), and yellow fever vaccine (Stamaril; Aventis Pasteur) were administered intramuscularly. OPV (Polio Sabin; GlaxoSmithKline Biologicals) was administered orally. Vaccinees were observed for 60 min after each vaccination. Assessment of reactogenicity and safety. Solicited reactogenicity data on adverse events (AEs; pain, swelling, drowsiness, fever, irritability, and loss of appetite) were collected for 7 d following each dose, and reports of unsolicited nonserious AEs were collected for 30 d following each dose. Grade 3 (severe) events were defined as follows: pain that caused the infant to cry when the limb was moved and/or was spontaneous, swelling of 120 mm in diameter, fever with an axillary temperature of у37.5ЊC (especially of 139ЊC), irritability (crying that could not be comforted) that prevented normal activity, drowsiness that prevented normal activity, and loss of appetite (not eating at all).
Serious AEs (SAEs) were recorded throughout the study period (months 0-8). All seizures occurring within 30 d after vaccination were reported as SAEs, and those occurring within 7 d were reported according to the Brighton Collaboration guidelines [18] .
Time points for the measurement of levels hematological function (hemoglobin, platelets, and white blood cells), renal function (creatinine), and hepatic function (alanine amino-transferase) are detailed in Table 1 . Clinically significant abnormal laboratory findings were reported as AEs or SAEs. Grade 3 abnormalities were predefined as follows: hemoglobin level, !5.0 g/dL; total white blood cell count, ! cells/ 3 1.4 ϫ 10 mL; platelet count, ! cells/mL; alanine aminotransferase 3 25 ϫ 10 level, 15.1 times the upper limit of the reference range; creatinine level, 13.1 times the upper limit of the reference range.
Assessment of immunogenicity. Time points for measurement of levels of antibodies against CS, HBsAg, diphtheria toxin, tetanus toxin, polyribosyl ribitol phosphate (PRP) for Hib, Bordetella pertussis toxin (BPT), polio 1, polio 2, polio 3, measles, and yellow fever antigens are detailed in Table 1 .
The levels of immunoglobulin G antibodies to CS were measured by a R32LR antigen-based enzyme-linked immunosorbent assay (ELISA) with a detection cutoff of 0.5 EU/mL, as described elsewhere [19] . Antibody levels were measured using an in-house ELISA for anti-HBsAg (seroprotective cutoff, 10 mIU/mL) [12] , anti-diphtheria (seroprotective cutoff, 0.1 IU/ mL), anti-PRP (Hib; seroprotective cutoff, 0.15 mg/mL), and anti-tetanus (seroprotective cutoff, 0.1 IU/mL). Antibody levels were measured for anti-BPT by use of a commercial immunoglobulin G ELISA (Anilabsystems; seropositivity cutoff, 115 EI.U/mL), for anti-measles immunoglobulin G by use of a commercial ELISA (Enzygnost; Dade Behring; seroconversion cutoff, 150 mIU/mL), for titers of anti-polio 1, anti-polio 2, and anti-polio 3 by use of a standard poliovirus microneutralization assay (median effective dose protective serum dilution factor, 8), and for anti-yellow fever by use of a yellow fever plaque reduction neutralization test (protective serum dilution factor, 10).
Statistical methods. Statistical analyses were conducted using SAS (version 8; SAS Institute). The trial sample size was calculated to give 90% power to detect a 2.5-fold difference (2sided; 5% significance) in the rate of a SAE occurring with a frequency of 10% in the control group compared to each of the experimental regimens. For secondary immunogenicity endpoints, the trial had 195% power to demonstrate noninferiority for all antigens except measles antigen, for which power was 82%, based on historical response rates.
Safety was analyzed on the total vaccinated cohort, which included all subjects with at least 1 documented study vaccine administration. The primary endpoint was the occurrence of SAEs from months 0-8. The proportion of subjects with a SAE, as classified by the preferred term in the Medical Dictionary for Regulatory Activities (MedDRA), was tabulated with exact 95% confidence intervals (CIs). Summaries were tabulated for the incidence, intensity, and relationship of solicited symptoms and unsolicited AEs, as classified by MedDRA preferred terms. According to protocol, all solicited local injection site symptoms were considered to be causally related to vaccination. Frequency distributions of biochemical and hematological parameters by severity grades were tabulated.
The primary analysis of immunogenicity was performed on the According to Protocol cohort, which included subjects who met all eligibility criteria, complied with the study procedures, and had no elimination criteria. Seropositivity, seroprotection, or seroconversion rates were defined with 95% CIs. Antibody titers were summarized by geometric mean titers (GMTs) with 95% CIs for all antigens.
For the analysis of noninferiority, the differences in anti-HBsAg, anti-diphtheria, anti-tetanus, anti-PRP, anti-polio 1, anti-polio 2, and anti-polio 3 seroprotection rates at month 3 and those in anti-measles and anti-yellow fever seroconversion rates at month 8 between the control group and RTS,S/AS01 E groups were calculated with 95% CIs (standardized asymptotic) around this difference. If the upper limit of the 2-sided 95% CI was !10%, then the noninferiority of the RTS,S/AS01 E groups compared with the control group was considered to be demonstrated. For anti-BPT, for which there is no demonstrated correlate of protection, the 95% CI (analysis of variance model; pooled variance) on the GMT ratio (GMT of the control group divided by that of the RTS,S/AS01 E group) was calculated. If the upper limit of this 95% CI was !1.5, then the noninferiority of the RTS,S/AS01 E groups compared with the control group was considered to be demonstrated. As a post hoc analysis, polio vaccine responses were investigated when taking into account polio antibody titers at screening. A polio vaccine response was defined as the appearance of antibodies at month 3 (titer, у8 EU/mL) in initially seronegative subjects or a 2fold increase in postvaccination antibody titers over prevaccination titers in initially seropositive subjects. Figure 1 summarizes subject participation during the course of the study. Age, sex, and weight were balanced between groups. The mean age of subjects at baseline was 7.0 weeks (standard deviation, 1.0 weeks), the mean weight at baseline was 4.9 kg (standard deviation, 0.6 kg), and 51% of the subjects were male. All participants had received a first dose of OPV and BCG vaccine in the neonatal period.
RESULTS

Subject cohort.
Safety outcome primary endpoint. From the time of the first vaccination until month 8, the proportion of subjects with a SAE was similar in all groups: 22.9% in the RTS,S/AS01 E (0, 1, 2) group, 18.2% in the RTS,S/AS01 E (0, 1, 7) group, and 21.1% in the control group (Table 2) . No SAE occurred with a clinically concerning higher incidence in either RTS,S/AS01 E groups compared with the control group.
No seizures occurred within 7 d after vaccination. Three seizures were reported within 30 d after vaccination, 2 in subjects from the RTS,S/AS01 E (0, 1, 7) group and 1 in a subject from the control group. Subjects in the RTS,S/AS01 E (0, 1, 2) group were vaccinated with RTS,S/AS01 E and DTPwHepB/Hib+OPV (diphtheria, tetanus, and whole-cell pertussis conjugate; hepatitis B; Haemophilus influenzae type b; and oral polio vaccine) at vaccine visits 1, 2, and 3 (doses 1, 2, and 3) and with measles and yellow fever vaccines at vaccine visit 4 (dose 4). Subjects in the RTS,S/AS01 E (0, 1, 7) group were vaccinated with RTS,S/AS01 E and DTPwHepB/ Hib+OPV at vaccine visits 1 and 2 (doses 1 and 2), with DTPwHepB/Hib+OPV at vaccine visit 3 (dose 3), and with RTS,S/AS01 E and measles and yellow fever vaccines at vaccine visit 4 (dose 4). Subjects in the control group were vaccinated with DTPwHepB/Hib+OPV at vaccine visits 1, 2, and 3 (doses 1, 2, and 3) and with measles and yellow fever vaccines at vaccine visit 4 (dose 4).
No SAE was considered by the investigator to be related to vaccination. One study participant in the control group died because of pneumonia and severe P. falciparum malaria with severe anemia.
Solicited AEs. The occurrence of solicited events following vaccination is summarized in Table 3 . No local solicited injec-tion site pain of grade 3 occurred. Grade 3 swelling was rare, occurring after р0.6% of doses of any vaccine in each study group.
Fever was reported more frequently in participants who received RTS,S/AS01 E in combination with DTPwHepB/Hib+OPV compared with participants who received DTPwHepB/Hib+OPV alone and in participants who received RTS,S/AS01 E in combination with measles and yellow fever vaccines compared with participants who received measles and yellow fever vaccines alone. Grade 3 fever was rare and balanced across vaccine groups. No grade 3 drowsiness or loss of appetite was reported. Unsolicited AEs. Unsolicited AEs were reported in similar proportions of subjects in the RTS,S/AS01 E (0, 1, 2), RTS,S/ AS01 E (0, 1, 7), and control groups (94.1%, 94.7%, and 95.9%, respectively) ( Table 2 ). Nasopharyngitis and upper respiratory tract infection were the most frequently reported unsolicited symptoms, occurring with a similar incidence in all study groups. Diaper dermatitis occurred more frequently in RTS,S/ AS01 E recipients than in control participants (8 subjects in the RTS,S/AS01 E [0, 1, 2] group, 9 subjects in the RTS,S/AS01 E [0, 1, 7] group, and 0 subjects in the control group).
Unsolicited AEs with a causal relationship to vaccination were reported with similar frequencies in all study groups (17.1% in the RTS,S/AS01 E [0, 1, 2] group, 18.2% in the RTS,S/ AS01 E [0, 1, 7] group, and 19.9% in the control group), predominantly because of reports of induration from 1 study cen- Other unsolicited AEs considered to be causally related to vaccination were as follows: injection site induration in 2 subjects, vomiting in 1 subject, and injection site cellulitis in 1 subject in the RTS,S/AS01 E (0, 1, 2) group; injection site induration in 4 subjects in the RTS,S/AS01 E (0, 1, 7) group; and injection site induration in 4 subjects and cough in 1 subject in the control group. With the exception of the subject who died, no subject withdrew from the study as a result of an AE. Laboratory safety monitoring. Of the few hematological and biochemical values outside the reference range, 2 values were grade 3 in severity; both occurred in subjects from the control group. One subject had a low hemoglobin concentration (4.1 g/dL) at month 8; no follow-up laboratory safety data were available for this subject, who was reported to have severe sickle cell disease, severe pediatric immune deficiency syndrome, and severe sepsis at the month 7 visit. One subject had an increased level of alanine aminotransferase (444 IU/L) 6 d after dose 1; alanine aminotransferase levels were within the reference range at month 3 and month 8 (25.0 IU/L and 12.6 IU/L, respectively).
Immunogenicity results. Across vaccine groups, 26%-30% of subjects had detectable anti-CS antibodies, at low titers, prior to RTS,S/AS01 E vaccination. At month 3, 99% of subjects in both the RTS,S/AS01 E (0, 1, 2) and RTS,S/AS01 E (0, 1, 7) groups had detectable anti-CS antibodies, compared with a low proportion of anti-CS seropositivity in the control group (11% of subjects). The highest anti-CS GMT of 190.3 EU/mL was observed 1 month after dose 3 (month 3) in the RTS,S/AS01 E (0, 1, 2) group, which compares with a GMT of 107.8 EU/mL 1 month after the third dose (month 8) in the RTS,S/AS01 E (0, 1, 7) group (Figure 2) .
Prevaccination anti-HBsAg GMTs were low and similar across vaccine groups (9-13 mIU/mL). At month 3, 100% of subjects in both RTS,S/AS01 E groups and 98% of subjects in the control group had protective levels of anti-HBsAg antibodies ( Table 4 ). The highest GMT (59,814 mIU/mL) was observed at month 8 in the RTS,S/AS01 E (0, 1, 7) group, compared with a GMT of 1356 mIU/mL at month 3 in the RTS,S/AS01 E (0, 1, 2) group and of 338 mIU/mL in the control group.
Noninferiority of anti-HBsAg, anti-diphtheria, anti-tetanus, anti-PRP, anti-polio 1, anti-polio 2, and anti-polio 3 seroprotection rates and anti-BPT antibody titers was demonstrated for the RTS,S/AS01 E (0, 1, 2) and (0, 1, 7) groups, compared with the control group, with the exception of anti-polio 3 in the RTS,S/AS01 E (0, 1, 2) group ( Table 4 ). Noninferiority of anti-measles and anti-yellow fever seroconversion rates was demonstrated for RTS,S/AS01 E coadministered with measles and yellow fever vaccines compared with measles and yellow fever vaccines given alone.
Seroprotective and seropositive antibody titers were similar and high for anti-HBsAg, anti-diphtheria, anti-tetanus, anti-PRP, anti-BPT, and anti-polio (serotypes 1 and 2) ( Table 4) . Seroprotection rates for anti-polio 3 were slightly lower in participants of the RTS,S/AS01 E (0, 1, 2) group (86.7% of sub- NOTE. Subjects with available postvaccination results were included in the analysis. BPT, Bordetella pertussis toxin; CI, confidence interval; GMT, geometric mean titer; HBsAg, hepatitis B surface antigen; Hib, Haemophilus influenzae type b; PRP, polyribosyl ribitol phosphate; S+, seropositive rate (percentage of subjects with antibody titers above the seropositive cutoff); SC, seroconversion rate (percentage of initially seronegative subjects who were seropositive after vaccination); SP, seroprotective rate (percentage of subjects with antibody titers above the seroprotective cutoff). jects). Seropositive levels for anti-measles and anti-yellow fever were similar across vaccine groups. A post hoc analysis of anti-polio responses was conducted to further explore the observed differences in anti-polio 3 responses induced by OPV in coadministration with RTS,S/AS01 E compared with administration of OPV without RTS,S/AS01 E . A heterogeneity across vaccine groups of anti-polio 3 titers, but not anti-polio 1 or anti-polio 2 titers (data not shown), was found at screening whereby a higher proportion of seronegative subjects was observed in the RTS,S/AS01 E (0, 1, 2) and RTS,S/AS01 E (0, 1, 7) groups compared with the control group ( and , respectively; Fisher exact test). An P p .015 P p .049 analysis of polio 3 antibody responses that took into account titers at screening revealed equivalent vaccine responses across the 3 groups (Table 5) .
At month 3, GMTs for anti-diphtheria, anti-tetanus, anti-PRP, anti-BPT, and anti-polio 3 serotypes tended to be lower in the RTS,S/AS01 E coadministration groups than in the control group. This effect was more marked when all 3 doses were given in coadministration (RTS,S/AS01 E [0, 1, 2] group) rather than when 2 doses were coadministered (RTS,S/AS01 E [0, 1, 7] group).
DISCUSSION
This is the first study of the RTS,S/AS01 E malaria candidate vaccine integrated into the EPI schedule, with vaccinations starting at 6 weeks of age. Overall, the study showed a favorable safety assessment of RTS,S/AS01 E incorporation into the EPI schedule, which is in line with previous results in which the closely related RTS,S/AS02 D vaccine was coadministered with EPI vaccines with a tetravalent DTPw/Hib vaccine in Tanzania [9] . Mild or moderate fever was reported more frequently in RTS,S/AS01 E coadministered groups than in control groups with EPI vaccines given alone, but grade 3 fever was rare in any of the study groups. The occurrence of SAEs during the whole reporting period and that of unsolicited AEs within 30 d after vaccination were reported in a similar proportion of NOTE. Subjects with both prevaccination and postvaccination results were included. Seronegative subjects had an antibody titer of !8 times the median effective dose (ED 50 ) prior to vaccination. Seropositive subjects had an antibody titer of у8 ED 50 prior to vaccination. For initially seronegative subjects, vaccine response was defined as an antibody titer at month 3 of у8 ED 50 . For initially seropositive subjects, vaccine response was defined as an antibody titer at month 3 of у2-fold the prevaccination antibody titer. Similar results were obtained when a 4-fold increase criterion was used (data not shown). CI, confidence interval; GMT, geometric mean antibody titer.
subjects in each study group; unsolicited AEs related to vaccination were predominantly due to reports of induration at 1 study center that were balanced across groups.
This study also assessed the antibody responses to coadministered EPI antigens. As in a previously reported trial in Tanzania [9] , GMTs to diphtheria, tetanus, BPT, Hib, and polio 3 antigens were slightly lower in the RTS,S/AS01 E coadministration groups than in the control group, more so when all 3 DTPwHepB/Hib+OPV vaccine doses were coadministered (RTS,S/AS01 E [0, 1, 2] group) than when 2 doses were coadministered (RTS,S/AS01 E [0, 1, 7] group). There was no interference with polio 1, polio 2, measles, and yellow fever responses upon coadministration. Overall, the seropositivity and seroprotection rates were high and in accordance with the expected rates of EPI antigen responses in resource-limited countries [20] [21] [22] [23] [24] , and the predefined noninferiority criteria were met for the DTPwHepB/Hib+OPV, measles, and yellow fever antigens, except for polio 3 antigen in the RTS,S/AS01 E (0, 1, 2) group.
An apparent interaction between an oral live attenuated vaccine and a recombinant injected vaccine was unexpected, and this finding may have been due to chance in the context of the multiple comparisons that were made. A post hoc analysis of the screening samples supports the view that the differences in the response to anti-polio 3 between groups may be related to a heterogeneity across groups in anti-polio 3 antibody levels at screening: there was a higher proportion of polio 3 seronegative subjects and lower polio 3 GMTs in both RTS,S/AS01 E groups at screening, in comparison with the control group. When polio type 3 immune responses were analyzed taking into account antibody levels at screening, as is frequently done when assessing polio immunization responses in infants [25, 26] , similar vaccine response rates were observed in all 3 groups. Further evaluation of OPV responses are planned as part of the ongoing phase 3 RTS,S/AS01 E clinical trial.
In terms of anti-CS responses, the results of this study confirm the induction of high anti-CS antibody responses by RTS,S/AS01 E vaccination; levels were well above the minimal responses induced by natural parasite exposure. The peak response following the third dose in both vaccination schedules in the study was higher than the peak following 2 doses, which supports previous results showing the superiority of a 3-dose schedule compared with a 2-dose schedule [12] . Also in line with results of a previous study in children aged 5-17 months in Ghana [11] , this study confirmed that a higher peak anti-CS response is induced by a schedule of vaccination at 0, 1, and 2 months compared with a schedule at 0, 1, and 7 months.
The RTS,S antigen is a recombinant construct that also expresses HBsAg. This study shows that RTS,S/AS01 E can be incorporated into the EPI with another HepB-containing combination vaccine without generating safety concerns. Higher anti-HBsAg GMTs were found in the RTS,S/AS01 E groups compared with those in the control group, which might be associated with the induction of longer lasting protection. Unlike the CS response, the HBsAg response was highest when the third RTS,S/AS01 E dose was delayed-in the schedule of vaccination at 0, 1, and 7 months compared with that at 0, 1, and 2 months, as was previously found in a RTS,S schedule study among slightly older children [11] . This is in line with a welldescribed characteristic of hepatitis B vaccination responses: the immune response to a delayed last immunization is higher than when it follows the previous doses closely [27, 28] .
In summary, this trial has shown a favorable safety and immunogenicity evaluation of the RTS,S/AS01 E malaria candidate vaccine introduced into the EPI on a schedule of vaccination at 0, 1, and 2 months or on a schedule at 0, 1, and 7 months. Because a schedule at 0, 1, and 2 months can be readily implemented in the EPI and may be associated with higher coverage compared with a schedule at 0, 1, and 7 months, the schedule at 0, 1, and 2 months has been selected for further assessment in the ongoing RTS,S/AS01 E phase 3 efficacy study.
